Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) EBITDA Margin (2024)

Historic EBITDA Margin for Compass Therapeutics (CMPX) over the last 1 years, with Q2 2024 value amounting to 1538.47%.

  • Compass Therapeutics' EBITDA Margin changed N/A to 1538.47% in Q2 2024 from the same period last year, while for Mar 2025 it was 6463.88%, marking a year-over-year change of. This contributed to the annual value of 5788.47% for FY2024, which is N/A changed from last year.
  • Compass Therapeutics' EBITDA Margin amounted to 1538.47% in Q2 2024.
  • In the past 5 years, Compass Therapeutics' EBITDA Margin registered a high of 1538.47% during Q2 2024, and its lowest value of 1538.47% during Q2 2024.